Trisha Shetty (Editor)

Corixa (company)

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Founder
  
Mark McDade

Number of locations
  
2

Founded
  
1994

Defunct
  
31 March 2006

Former type
  
biotechnology/pharmaceutical

Successor
  
acquired by GlaxoSmithKline

Headquarters
  
Seattle, Washington, United States

Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.

The name Corixa comes from the true bug (Insecta: Hemiptera: Heteroptera) genus Corixa (family Corixidae, Water boatman), described by Geoffroy, in 1762.

On 12 July 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa. GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.

On 31 March 2006, Corixa's doors closed after over 11 years in business.

References

Corixa (company) Wikipedia